500 patients67,039 observations150 daysLIVE

Patient P-03258

Synthetic patientONX-7 · Day 105 · 45–54 · M · baseline S14Open companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
22%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 38 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 39 Patient acceptedStarted NP-02 in the companion
  4. Day 49 No meaningful changeDietary Support Protocol NP-02

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Nutritional resilience-8
  • Toxicity+4
  • Inflammatory activity+3
  • GI instability-2

What helped?

  • Dietary Support Protocol NP-02Day 38
    Result: no meaningful change
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients.

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 70
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • WearableSleep 5.9 h, below personal baseline
  • Inflammatory signalling 60
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • WearableHRV 36 ms, trending down
  • Drug metabolism and exposure 40
    • DNACYP2D6 poor metabolizer → higher exposure
  • Butyrate / short-chain fatty acid production 25
    • MicrobiomeF. prausnitzii depleted
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 3.6 · butyrate capacity 45/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
40 ms
Sleep
6.0 h
Steps
6,318
Resting HR
71 bpm
Daily log: GI score 18, nutritional resilience 61, adherence 96.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0335658%S1466
P-0343558%S0864
P-0319657%S0560
P-0342757%S0260
P-0346155%S0362
P-0329654%S1660
P-0338154%S0155
P-0342853%S1662
P-0300652%S1066
P-0305752%S14NP-02improved64
P-0310552%S12AD-05no change60
P-0310752%S1762